In: Uncategorized
Further commentaries, articles and blog posts – September 2017
September 28, 2017Paul Glasziou and Iain Chalmers: Funders and regulators are more important than journals in fixing the waste in research Exzellenztheater: Zeit…
Read MoreNew PAASP member
September 1, 2017We are delighted to announce that Malgorzata Pietraszek has joined our PAASP Team. Malgorzata has over 20 years of experience in…
Read MoreWhat do PAASPort and Coca-Cola have in common?
August 17, 2017PAASPort is our tool to evaluate bias in preclincical drug discovery research. Application of PAASPort is based on the analysis of…
Read MoreNPG’s Policy on authorship
August 17, 201708.09.2011: NPG’S POLICY ON AUTHORSHIP – Important change to submission criteria “To the dismay of many (yet to the delight of…
Read MorePAASP is launching new web page
August 16, 2017After founding PAASP almost two years ago and with the important upcoming projects, it was time to give the web interface…
Read MorePAASP member was invited to a meeting organised by NIH
June 25, 2017June 5, 2017 – Anton Bespalov took part in a meeting in Washington, DC (USA) hosted by Francis Collins, Director of…
Read MoreMeeting report – PAASP at the 5th World Conference on Research Integrity (WCRI)
June 7, 2017Björn Gerlach attended the 5th WCRI, which was held in Amsterdam from May 28th to May 31st. With over 800 participants,…
Read MoreMeeting Report – Washington, DC
June 7, 2017June 5, 2017 – Anton Bespalov took part in the meeting in Washington, DC (USA) hosted by Francis Collins, Director of…
Read MoreRigor, Reproducibility and in vitro CSF assays: The Devil in the Details
May 19, 2017This is not a new story and at least some of our readers may be familiar with the conflicting results regarding…
Read MoreWhat does the Net Present Value have to do with preclinical drug discovery research?
May 5, 2017When looking for Investors in the Life Science sector, entrepreneurial scientists and start-up companies have to deal with an unavoidable questions:…
Read More